Is Tirzepatide currently available in domestic pharmacies?

Tirzepatide (Tirzepatide) has not yet been officially launched in China, which means that patients cannot purchase the drug directly in domestic pharmacies. Although this drug has been approved in many countries around the world and has shown good therapeutic effects, tilsiparatide is still in the waiting stage in the Chinese market due to the approval process and market access. Therefore, if domestic patients want to use tilsiparatide, they need to obtain it through other formal channels.

For patients who urgently need tisiparatide, formal overseas drug purchase channels have become a feasible option. Currently, the European version of the original drug tilsiparatide is sold in overseas markets, and the price is relatively high. The latest price of each drug is about 3,000 to 4,000 yuan. When purchasing drugs through these channels, patients should pay attention to the authenticity of the drugs and the safety during transportation. It is best to choose a reputable drug supplier or medical institution for purchase to ensure the safety and effectiveness of the drugs.

It is worth mentioning that tilsiparatide, as a new type of hypoglycemic drug, is mainly used to treat patients with type 2 diabetes, especially in terms of weight management and blood sugar control. As the domestic demand for such innovative drugs increases, tilsiparatide is expected to be approved by domestic drug regulatory authorities and enter the market in the future, which will greatly facilitate patients' medication choices and reduce drug purchase costs.

In general, although tilsiparatide is not currently available in domestic pharmacies, patients can obtain it through regular overseas channels. In terms of price, the European version of the original drug is priced at about 3,000 to 4,000 yuan per vial. In the future, with the advancement of domestic approval and the improvement of the supply chain, tisipatide is expected to enter the Chinese market as soon as possible and bring good news to more diabetic patients.

Reference materials:https://www.drugs.com/tirzepatide.html